Condition

Mental Disorders

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 53 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials53

Recruiting4

Common interventions25

Lead sponsors shown15

Clinical trials

53 shown

Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in SchizophreniaNCT06673966 · 2025-01-10

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant DepressionNCT06511908 · 2024-11-06

Biobank and Brain Health in Bordeaux.NCT05322343 · 2022-03-22

Psychiatric Multi-omics and Neuroimaging ProjectNCT06580860 · 2016-01-01

Effects of ACT-Based Psychoeducation on Caregivers of Individuals With Mental DisordersNCT07643714 · 2025-10-06

A Trial of Extended Reality Activities to Enhance Leisure Participation Among Inpatients With Persistent Mental Health ConditionsNCT06964477 · 2025-07-01

NOT_YET_RECRUITING

Common Factors Group Psychotherapy for General Mental Health ConcernsNCT06614842 · 2025-01-17

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationNCT05321498 · 2023-06-01

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486 · 2023-02-28

ACTIVE_NOT_RECRUITING

An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387 · 2023-02-21

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789 · 2022-10-10

ACTIVE_NOT_RECRUITING

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976 · 2022-02-28

Harmony at Home: A Pilot Telehealth Program for Rural ADRD CaregiversNCT05202223 · 2022-01-15

Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care SystemsNCT05080777 · 2021-09-28

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderNCT05321602 · 2021-09-08

The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) StudyNCT05007353 · 2021-08-23

Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Diseases.NCT05125458 · 2021-04-01

Addressing Anxiety and Stress for Healthier Eating in TeensNCT05038033 · 2021-02-22

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese PopulationNCT05527288 · 2021-01-28

Relative Bioavailability of LY03010 Compared to Listed DrugNCT04922593 · 2021-01-13

Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia PatientsNCT02897167 · 2016-08-01

Impact of Aerobic Exercise on Metabolic Syndrome, Neurocognition and Empowerment in Individuals With Mental DisordersNCT02858102 · 2016-06-01

STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in SchizophreniaNCT02744989 · 2016-05-30

CNS Tau Kinetics in Healthy Aging and Alzheimer's DiseaseNCT03938870 · 2015-08-18

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient CareNCT02487888 · 2014-09-01

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious DistressNCT02196506 · 2014-07-01

A System for Preference Assessment in Mental HealthNCT02183844 · 2014-06-16

Implementation of Illness Management and Recovery in Mental Health ServicesNCT02077829 · 2014-03-01

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialNCT01727726 · 2012-12-01

Clinical Monitoring to Facilitate Continuous Care for Substance Abusing ClientsNCT01831999 · 2012-06-01

Web-Based Weight Management for Individuals With Mental IllnessNCT01324973 · 2012-03-01

The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-ADNCT01696591 · 2012-03-01

A Community-health Worker Delivered HIV/STI Prevention Intervention for Internally Displaced Women in Leogane, HaitiNCT01492829 · 2012-01-01

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)NCT01360866 · 2011-10-01

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)NCT01360645 · 2011-07-01

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)NCT01360632 · 2011-06-01

A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy SmokersNCT01371799 · 2009-12-17

Effects of Delta-9-THC and Iomazenil in Healthy HumansNCT00982982 · 2009-02-11

Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset SchizophreniaNCT00757497 · 2008-09-17

Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune MechanismsNCT00690196 · 2008-03-01

Cognitive Remediation in Supported Employment at Human Service Center (HSC)NCT00138021 · 2005-07-01

A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of AdolescentsNCT00163865 · 2005-05-01

Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy MotivationNCT00137189 · 2005-04-01

Psychiatric Problems in Children and Adolescents Infected With HIV at BirthNCT00100542 · 2005-04-01

A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)NCT00294008 · 2004-12-01

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive ImpairmentNCT00240695 · 2003-05-01

Naltrexone Treatment of Alcohol Abuse in SchizophreniaNCT00145847 · 2003-04-01

A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseNCT00291421 · 2002-07-01

CAFE Comparison of Atypicals in First Episode of PsychosisNCT00034892 · 2002-03-01

A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I DisorderNCT00035802 · 2002-01-01

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseNCT00216502 · 2001-08-01

Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's DiseaseNCT00034762 · 2000-12-01

To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI).NCT00007709 · 1998-01-01

Common interventions

Leading sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. 5 Inmune Bio, Inc. 3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 3 Eli Lilly and Company 2 Fundación Marques de Valdecilla 2 Luye Pharma Group Ltd. 2 National Institute of Mental Health (NIMH) 2 University of California, Los Angeles 2 AstraZeneca 1 Bayside Health 1 Central South University 1 Chia-Hui Hung 1 Duk Lyul Na 1 Elizabeth K Rhodus 1 GlaxoSmithKline 1

Trial status mix

COMPLETED37

UNKNOWN5

RECRUITING4

ACTIVE_NOT_RECRUITING2

TERMINATED2

WITHDRAWN2

NOT_YET_RECRUITING1

Phase mix

NA18

PHASE312

PHASE15

PHASE24

EARLY_PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.